Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY22 results · Jul–Sep 2021
Bliss GVS Pharma reported revenue from operations of ₹195.99 crore (up 29.3% from Q2 FY21) and net profit of ₹22.06 crore (up 2.1% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 195.99 | 151.54 | +29.3% | 168.15 | +16.6% |
| Other income | 5.45 | 2.74 | +98.8% | 7.82 | −30.3% |
| Total income | 201.44 | 154.28 | +30.6% | 175.96 | +14.5% |
| Profit before tax | 29.89 | 30.05 | −0.6% | 36.69 | −18.5% |
| Net profit for the period | 22.06 | 21.61 | +2.1% | 26.13 | −15.6% |
| Attributable to shareholders of the company | 21.27 | 20.51 | +3.7% | 24.25 | −12.3% |
| EPS, basic (₹) | 2.05 | 1.99 | +3.0% | 2.35 | −12.8% |
| Net margin (%) | 11.3 | 14.3 | 15.5 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 174.43 | 118.83 | +46.8% | 133.03 | +31.1% |
| Other income | 5.99 | 3.18 | +88.3% | 7.90 | −24.2% |
| Total income | 180.41 | 122.00 | +47.9% | 140.93 | +28.0% |
| Profit before tax | 34.77 | 26.27 | +32.4% | 29.04 | +19.7% |
| Net profit for the period | 24.73 | 18.79 | +31.6% | 21.66 | +14.2% |
| EPS, basic (₹) | 2.39 | 1.82 | +31.3% | 2.10 | +13.8% |
| Net margin (%) | 14.2 | 15.8 | 16.3 |
Consolidated
- Filed with BSE
- 30 Oct 2021, 20:16 IST
- Board meeting
- 30 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2021, 20:16 IST
- Board meeting
- 30 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE